What is the recommended primary care management and next steps for a patient diagnosed with severe fatty liver disease (steatosis)?

Management of Severe Fatty Liver (Steatosis) in Primary Care

The immediate next step is to risk-stratify for advanced liver fibrosis using the FIB-4 score (or NAFLD Fibrosis Score), as the finding of steatosis—especially when severe—mandates assessment for clinically significant fibrosis that determines prognosis and need for specialty referral 1, 2.

Step 1: Calculate FIB-4 Score Immediately

The FIB-4 score uses age, AST, ALT, and platelet count—all readily available in primary care. This is your first-line risk stratification tool 1, 2:

• FIB-4 <1.3 (or <2.0 if age >65): Low risk for advanced fibrosis

  • Manage in primary care
  • Repeat FIB-4 in 2-3 years 2

• FIB-4 1.3-2.67: Indeterminate risk

  • Requires second-tier testing with vibration-controlled transient elastography (FibroScan), ultrasound shear wave elastography, or Enhanced Liver Fibrosis (ELF) test 1, 3
  • Can be done in primary care if available, or refer for this testing

• FIB-4 >2.67: High risk for advanced fibrosis (60-80% positive predictive value)

  • Refer to hepatology/gastroenterology 1, 2

Critical caveat: Do not rely solely on liver enzymes (ALT/AST) to assess disease severity—patients can have normal liver tests yet still have advanced fibrosis 1. The term "severe steatosis" refers to fat content, not fibrosis stage, and fibrosis is what determines morbidity and mortality.

Step 2: Initial Workup While Awaiting Fibrosis Assessment

Perform these tests to exclude other causes and assess metabolic comorbidities:

• Alcohol screening: Use AUDIT-C or single-question screening tool 2
• Viral hepatitis: HBsAg, anti-HCV antibody
• Metabolic panel: Fasting glucose or HbA1c, lipid panel
• Screen for metabolic syndrome components: Blood pressure, waist circumference, presence of type 2 diabetes
• Complete blood count: Needed for FIB-4 calculation and to detect thrombocytopenia (suggests cirrhosis)

Step 3: Initiate Lifestyle Management Immediately (Don't Wait for Fibrosis Results)

Weight loss is the cornerstone of treatment and should begin now 4:

• Target ≥5% weight loss for patients with overweight/obesity to improve steatosis
• ≥7-10% weight loss can improve fibrosis 4
• ≥150 minutes/week of moderate aerobic exercise 4
• Dietary counseling: Mediterranean diet pattern, reduce refined carbohydrates and saturated fats
• Smoking cessation if applicable
• Alcohol: Recommend complete abstinence if any fibrosis; limited intake (<140g/week women, <210g/week men) if no/mild fibrosis 4, 5

Step 4: Aggressively Manage Cardiometabolic Risk Factors

NAFLD/MASLD patients die more often from cardiovascular disease than liver disease, so this is critical for mortality reduction 1:

• Type 2 diabetes: Optimize glycemic control; consider GLP-1 receptor agonists (semaglutide has FDA approval for MASH with fibrosis and improves liver outcomes) 4
• Dyslipidemia: Treat per cardiovascular risk guidelines; statins are safe in NAFLD 6
• Hypertension: Treat to target
• Screen for cardiovascular disease risk

Step 5: Determine Referral Pathway Based on FIB-4 Results

Refer to hepatology if 1, 2:

• FIB-4 >2.67 (high risk for advanced fibrosis)
• Indeterminate FIB-4 with high-risk second-tier test (e.g., liver stiffness >10-12 kPa on elastography)
• Diagnostic uncertainty about etiology
• Consideration for NASH drug therapies (resmetirom, semaglutide for F2-F3 fibrosis) 4
• Evidence of cirrhosis (needs HCC surveillance, variceal screening)

Manage in primary care if 1:

• FIB-4 <1.3 (<2.0 if >65 years)
• Low-risk second-tier testing if indeterminate FIB-4
• Continue lifestyle interventions
• Manage metabolic comorbidities
• Repeat FIB-4 every 2-3 years

Step 6: Patient Education

Provide written information and direct patients to credible resources 1:

• British Liver Trust (www.britishlivertrust.org.uk)
• NHS website for liver disease information
• Explain that this is a metabolic condition requiring long-term lifestyle changes
• Emphasize cardiovascular risk, not just liver risk

Common Pitfalls to Avoid

1. Don't assume normal ALT means no significant disease—up to 50% of patients with NAFLD have normal aminotransferases 1
2. Don't order unnecessary liver ultrasound if already diagnosed—move directly to fibrosis risk stratification in high-pretest-probability patients 2
3. Don't delay lifestyle intervention while waiting for specialty referral—weight loss and metabolic management should start immediately
4. Don't forget cardiovascular risk assessment—this is often the primary cause of mortality in these patients 7, 6
5. Don't use FIB-4 cutoffs incorrectly in elderly patients—use <2.0 threshold for those >65 years 2

The evidence strongly supports this algorithmic approach, with the 2022 British guidelines 1 and 2021 Gastroenterology clinical care pathway 2 providing the highest-quality consensus recommendations for primary care management.